CGRP antibodies for migraine prevention — new kids on the block

In the past few years, a number of new migraine treatments have emerged, including monoclonal antibodies against calcitonin gene-related peptide (CGRP) and the CGRP receptor. Now, a position statement from the American Headache Society offers guidance on the integration of these agents into clinical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Neurology 2019-03, Vol.15 (3), p.129-130
1. Verfasser:	Diener, Hans-Christoph
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/375/1654 692/699/375/226 692/700/565 Antibodies Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Associations Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use Children Development and progression Genes Headache Health aspects Humans Medicine Medicine & Public Health Migraine Migraine Disorders - drug therapy Monoclonal antibodies Nervous system diseases Neurology Neuropeptides News & Views news-and-views Peptides Prevention Preventive medicine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the past few years, a number of new migraine treatments have emerged, including monoclonal antibodies against calcitonin gene-related peptide (CGRP) and the CGRP receptor. Now, a position statement from the American Headache Society offers guidance on the integration of these agents into clinical practice in the prevention of migraine.
ISSN:	1759-4758 1759-4766
DOI:	10.1038/s41582-019-0139-7